Alex Balcom, MBA, CPA

Alex joined Nuvalent as Chief Financial Officer in January 2021, bringing over 15 years of strategic, financial and operational experience in the biotechnology industry to her role.

Prior to joining Nuvalent, she served as Vice President of Finance at SQZ Biotechnologies, where she was responsible for strategic planning, finance and accounting. During her time at SQZ Biotechnologies, she helped raise over $200 million in private and public equity financing, including the 2020 initial public offering. Before joining SQZ, Alex served as Corporate Controller at Agios Pharmaceuticals, where she built the finance and accounting teams and contributed to the company’s strategic financing efforts, raising more than $700 million in equity financing, including playing a key role in the 2013 initial public offering. Alex was responsible for all financial functions of the company including strategic planning, treasury, tax, finance and accounting. Earlier in her career, Alex held positions at both Molecular Insight Pharmaceuticals, a publicly-traded oncology company, acquired in 2013 and Coley Pharmaceuticals, a publicly-traded company developing immunotherapies for cancer and other disease areas, acquired by Pfizer in 2007.  

Alex earned her B.B.A in finance from the University of Massachusetts, Amherst and her M.B.A from Boston College. Alex is also a certified public accountant in Massachusetts.